Recorded device evidence

Stat Profile Prime Plus Analyzer System (K200403): indications, design and recorded evidence

The acquired K200403 file contains product-specific indications and users, design and operating principle, performance evidence actually described sections. Compare these dated manufacturer statements with your own indication and design before commissioning evidence work. They describe this submission; they do not prescribe your testing, validate performance independently or establish a suitable predicate.

Evidence retrieved 2026-10-07. Source versions and topic-specific limits are listed below.

Computed exact-code research

This decision beside its recorded product-code cohort

The 2021–2025 complete-year cohort contains 4 selected decisions under primary code JGS. 4 have valid reported receipt/decision pairs; 0 pairs are missing or invalid.

No quartiles are displayed: this complete-year cohort has fewer than 20 valid pairs.

The table shows the named decision and up to four latest exact-code research records through 2026-09-27. It can include partial-year records outside the complete-year cohort. The quartiles above use the full stated cohort, not this displayed selection.

Research recordRecorded deviceReceipt → decisionCalendar elapsed daysRecorded submission type
K200403 ↗ · this pageStat Profile Prime Plus Analyzer System2020-02-19 → 2020-04-1455Traditional
K252475 ↗ABL90 FLEX PLUS System2025-08-07 → 2026-05-01267Traditional
K230275 ↗i-STAT CG8+ cartridge with the i-STAT 1 System2023-02-01 → 2023-10-27268Traditional
K222438 ↗A-LYTE® Integrated Multisensor (IMT Na K Cl)2022-08-12 → 2023-07-25347Traditional
K220977 ↗ISE Reagents, Glucose, CRP Latex, DxC 500 AU Clinical Chemistry Analyzer2022-04-04 → 2023-07-20472Traditional

Use this comparison: select a record to investigate, read its actual indications and design, and document differences. A shared code or elapsed period cannot establish its relevance to your device.

Calendar elapsed days are not active FDA review time, a promised schedule or a success probability. The selection includes only the stated recorded decisions, not all applications. Latest records can postdate the named historical decision and are contextual research, not its predicates. Shared codes, summaries and observed records do not prove equivalence, current market availability, buyer applicability or predicate suitability.

Calculation, selection and source versions

Reuse the complete-endpoint exact-primary-code, documented SE-decision cohort and its stated cutoff/window. Retain its type-7 quartiles only when at least 20 valid date pairs are present. Independently subtract the named official record’s receipt date from its decision date; missing or negative pairs remain unknown. Show up to four latest exact-code research records, excluding the named ID. Parent analysis hash, source snapshots and calculation versions are retained.

Calculation: fda-named-decision-cohort-context-1; cutoff 2026-09-27; 0 parent records excluded; units record counts; calendar elapsed days.

Source snapshots: 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002.

Read beyond the decision row

Recorded evidence and differences to investigate

The summary is manufacturer-submitted context hosted by FDA. Negative/no-study statements are preserved. Evidence themes are not binding legal requirements.

Short opening excerpts identify the source sections. Read the linked original for the full study context, negative statements, tables and limitations. Public quotations are limited to 120 words per acquired summary; the internal evidence packet retains exact section ranges for review.

Indications and users

K200403 · PDF page 6 ↗ Source 2

Sodium (Na)                  Sodium measurements ar e used in the diagnos is and treatment of aldoster onism,
                               diabetes insipidus, adrenal hypertens ion, Addison’s dis ease, dehydration, or
                               diseases involv ing electroly te imbalance.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

Design and operating principle

K200403 · PDF page 4 ↗ Source 3

The Stat Profile Prime Plus Analyzer System is a low cost, low maintenance analyzer for hospital
  laboratory and point-of-car e settings. It consists of the analyzer, sensor cartridges, and thermal paper for
  an onboard printer.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

Performance evidence actually described

K200403 · PDF page 6 ↗ Source 2

Bench testing was previously completed and summar ized in k180428  to show that the Stat Profile Pr ime
Plus Analyzer demonstrates substantial equivalence to the predicate submission.

Compare with your product: The source labels this section as performance data. Determine which described evidence is bench, software, biological or clinical from the actual narrative and original tables; the section label alone does not settle that distinction or prescribe your testing.

Extraction selection and limits

Select observed whole-line section headings or explicit colon-delimited inline labels on readable PDF pages, including the explicitly documented heading-spacing variants in this parser version. Preserve the original heading, character ranges and layout; do not repair excerpt text. Exclude letter boilerplate and uncertain pages. Stop at observed table headings; do not infer table columns or scalar results from layout text. Multi-column or suspicious split-numeric excerpts are excluded until reviewed alternate extraction is available. Original layout records remain retained; any alternate text has its own extractor-version locator and requires original-page review. For each dimension, prefer usable versioned alternate text where available, selecting its longest usable excerpt; otherwise select the longest usable original-layout excerpt. Ties preserve source order. Bounded to 64 PDF pages and 3,500 characters per section. This is a selection, not a complete dossier analysis.

Excluded extraction items: {}.

Known facts and deciding inputs

Known context: US. Confirm the organisation’s role, relevant activities and markets against the cited criteria.

Source factRecorded valueWhat to check
510(k) identifierK200403 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Generic device categoryStat Profile Prime Plus Analyzer System [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded applicantNova Biomedical Corporation [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
FDA product codeJGS [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Decision date2020-04-14 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded decision codeSESE [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Submission typeTraditional [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Receipt date2020-02-19 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.

Prepare a differences and evidence worksheet

Use this checklist to gather your business or product details before speaking with a specialist. The items below explain what to record and suggest useful supporting documents. You can add your own answers in the editable project brief.

  1. Indications and users — what differs in our product?

    Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

    Useful evidence: Our proposed indication, user/population and use environment beside this exact recorded indication.

  2. Design and operating principle — what differs in our product?

    Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

    Useful evidence: Design description, materials/components, accessory list and a differences matrix.

  3. Performance evidence actually described — what differs in our product?

    The source labels this section as performance data. Determine which described evidence is bench, software, biological or clinical from the actual narrative and original tables; the section label alone does not settle that distinction or prescribe your testing.

    Useful evidence: The cited narrative and full tables, underlying protocols/results and a reviewed comparison with the proposed product.

Work packages and dependencies

Questions for providers

Sources and data dates

Read the official document in context. The audit details identify the precise locators and preserved versions used for this page.

FDA openFDA — 510(k) decision records ↗

2026-10-05 · retrieved 2026-10-06

Audit details: precise locators and snapshot identifiers

Source key D01 · snapshot 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002

  • [1] device-510k-0001-of-0001.json:results[77198] · record 69eb2f069b744027ffb3c704a96e8ea5d4239b545bf4244b65092ee9b76f4567
  • [4] Complete results array / fda-decision-context:K200403 · record whole dataset partition

FDA 510(k) summary — K200403 ↗

Tue, 05 May 2020 10:09:32 GMT · retrieved 2026-10-07

Audit details: precise locators and snapshot identifiers

Source key D02 · snapshot 897beefa2d8a0c934de16c10d6633b1512dad9e5473f7adf4174b66698feff88

  • [2] PDF page 6 · record b9aac1f9fb06b33fb552fa92bb2906e1eb87d389f435d6dbe2ae713f12f4d582
  • [3] PDF page 4 · record c9ecebacfb61ccd97dd33bd7af8cdb4e910b270ac62e548b5a88e4c5c4968484

Prepare an editable project brief

Confirm the facts, scope and contact preference before sharing your project. Preparing this page sends no provider outreach.

Choose work packages to discuss

Compare FDA 510(k) Submission Services